Skip to main
QTTB
QTTB logo

QTTB Stock Forecast & Price Target

QTTB Analyst Ratings

Based on 7 analyst ratings
Buy
Strong Buy 14%
Buy 29%
Hold 57%
Sell 0%
Strong Sell 0%

Bulls say

Q32 Bio Inc demonstrates a strong outlook due to the promising data from its lead product candidate, bempikibart, which has shown an attractive pharmacokinetic/pharmacodynamic profile and improved tolerability in clinical trials for atopic dermatitis and alopecia areata. Notably, the drug achieved a 16% reduction in the severity of alopecia areata in a Phase 2 post-hoc analysis and reported a 76% improvement in the average Eczema Area and Severity Index (EASI) score, underscoring its potential effectiveness compared to existing treatments. Furthermore, the company has increased the probability of success for its alopecia areata opportunity to 75%, reflecting heightened confidence in its therapeutic candidates amidst a growing market for novel biologics targeting autoimmune and inflammatory conditions.

Bears say

Q32 Bio Inc is experiencing a negative outlook due to several fundamental issues, including modest efficacy signals in their lead product candidates that fall significantly below market expectations. The company has recently faced disappointing topline results from critical Phase II studies, leading to concerns about the applicability of their mechanism of action in targeted indications, which further hampers investor confidence. Additionally, there are ongoing concerns regarding cash flow and the potential need for the company to raise funds in the market before achieving profitability, compounding the risks associated with its research and development endeavors.

QTTB has been analyzed by 7 analysts, with a consensus rating of Buy. 14% of analysts recommend a Strong Buy, 29% recommend Buy, 57% suggest Holding, 0% advise Selling, and 0% predict a Strong Sell.

This aggregate rating is based on analysts' research of Q32 Bio Inc and is not a guaranteed prediction by Public.com or investment advice.

Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy

FAQs About Q32 Bio Inc (QTTB) Forecast

Analysts have given QTTB a Buy based on their latest research and market trends.

According to 7 analysts, QTTB has a Buy consensus rating as of Jul 25, 2025. This rating is provided by third-party analysts and is not investment advice from Public.com.

Wall Street analysts have set a price target of $24.71, reflecting a 0.00% increase from the current stock price.

Financial analysts have set a price target of $24.71, indicating a 0.00% increase from the current stock price, but ratings and forecasts are frequently updated based on market conditions, earnings reports, and industry trends. This prediction is provided by third-party analysts and is not investment advice from Public.com.

Q32 Bio Inc (QTTB)


Order type

Buy in

Order amount

Est. shares

0 shares

Sign up to buy
Disclaimer: Any investment listed here, which may be available on the Public platform, is intended to be used for informational purposes only, should not be the sole basis for making an investment decision, and is not a recommendation or advice.